The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of DNA repair genetic alterations identified by circulating tumor DNA on sensitivity to radium-223 in bone metastatic, castration-resistant prostate cancer.
 
Steven Blinka
No Relationships to Disclose
 
Sarah Holt
No Relationships to Disclose
 
Aaron Lin
No Relationships to Disclose
 
Daniel Lim
No Relationships to Disclose
 
Jorge Ramos
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
 
Thomas Murphy
No Relationships to Disclose
 
Nathan Conrad
No Relationships to Disclose
 
Chelsea Brammeier
No Relationships to Disclose
 
Jarey Wang
No Relationships to Disclose
 
John Floberg
No Relationships to Disclose
 
Jessica Hawley
Employment - Johnson & Johnson/Janssen
Consulting or Advisory Role - Daiichi Sankyo/Lilly; GlaxoSmithKline; ImmunityBio
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Crescendo Biologics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Vaccitech (Inst)
 
Heather Cheng
Consulting or Advisory Role - Janssen Oncology
Research Funding - Clovis Oncology (Inst); Janssen (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Todd Yezefski
Consulting or Advisory Role - Dendreon
 
Andrew Hsieh
Honoraria - Hotspot Therapeutics
Research Funding - Denali Therapeutics
Patents, Royalties, Other Intellectual Property - MTOR modulators and uses thereof Patent number: 9629843; USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT Publication number: 20140288097
 
Justin Thomas
No Relationships to Disclose
 
Ana Kiess
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Bayer (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd.
Travel, Accommodations, Expenses - Novartis
(OPTIONAL) Uncompensated Relationships - Novartis; POINT Biopharma
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Janssen medical Affairs
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
 
Colin Pritchard
Consulting or Advisory Role - Sana Biotechnology
Research Funding - Color Genomics (I)
 
Evan Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol Myers Squibb; Janssen; Loxo/Lilly; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Oncternal Therapeutics (Inst); Seagen (Inst); Tyra Biosciences (Inst)